Coloplast stock slips after strong quarter and margin surge

Published on 09/14/2026 at 20:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coloplast stock fell 1.35 percent on Nasdaq Copenhagen on September 14, 2026, after an earlier quarter where operating profit jumped 82 percent. The Danish medical-device group is adjusting to a new chief executive following the margin-driven start.

Pop-Art-Comic-Illustration einer lächelnden Pflegekraft mit medizinischen Pflegeprodukten — Coloplast A/S (DK0060448595) als Medizintechnik-Firma inspiriert diese farbenfrohe Pop-Art-Comic-Szene mit einer freundlichen Pflegekraft dargestellt, Illustration mit AI erstellt.

Coloplast stock traded lower on Nasdaq Copenhagen on September 14, 2026, with Coloplast B A/S down 1.35 percent at DKK 446.70, even as the Danish medical-device group recently reported an 82 percent jump in operating profit for its latest quarter under a new chief executive.

Operating profit jumps under new CEO

Coloplast A/S (ISIN DK0060448595) has highlighted a markedly stronger earnings picture in its most recent reported quarter, with operating profit rising 82 percent compared with the same period a year earlier, giving the group and its new chief executive an unusually strong opening quarter.

According to Nordic Observer on August 18, 2026, the 82 percent increase in operating profit was driven by a margin surge that the new chief executive, who took over in May 2026, described as a satisfactory start in the company’s earnings report.

Stock retreat contrasts with earnings strength

On September 14, 2026, exchange data from Nasdaq Copenhagen showed Coloplast B A/S among the notable decliners in the Danish large-cap segment, with the shares down 1.35 percent at a last price of DKK 446.70, placing the stock in the group of names classified as tapers on the day.

Per market data published by Nordnet on September 14, 2026, Coloplast B A/S declined 1.35 percent to DKK 446.70, underperforming Danish peers such as Carlsberg B A/S, which gained 2.20 percent to DKK 890.20, and Genmab A/S, which advanced 1.12 percent to DKK 2,165.00.

The combination of an 82 percent year-on-year increase in operating profit in the latest quarter and a same-day share price decline of 1.35 percent suggests that investors are weighing the inherited margin strength against broader market factors and valuation, with Coloplast stock not yet fully reflecting the recent profit surge in its September 14, 2026 trading level.

Coloplast stock level on Nasdaq Copenhagen

As of the close of trading documented on September 14, 2026, Coloplast stock on its primary listing, Nasdaq Copenhagen, stood at DKK 446.70 for the B share, representing a 1.35 percent decline on the day and confirming the Danish market as the reference venue for the issuer’s equity.